Equillium is a biotechnology company developing products for autoimmune and inflammatory disorders. It offers Itolizumab, amonoclonal antibody that targets the CD6-ALCAM signaling pathway; EQ101, a tri-specific inhibitor of IL-2, IL-9, and IL-15, three inflammatory cytokines implicated in multiple diseases; EQ102, a selective inhibitor of IL-15 and IL-21 for treatment of gastrointestinal diseases.